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ABSTRACT 76 
Cisplatin is a commonly used chemotherapeutic agent. Its main side-effect is 77 
nephrotoxicity. It was reported that the organic anion transporter 5 (Oat5) urinary excretion is 78 
elevated, implying renal perturbation, when no modifications of traditional markers of renal 79 
damage are still observed in cisplatin-induced acute kidney injury (AKI). It was also 80 
demonstrated that Oat5 is excreted in urine by the exosomal pathway. This study was designated 81 
to demonstrate the specific response of the urinary excretion of exosomal Oat5 to kidney injury 82 
independently of other cisplatin toxical effects, in order to strengthen Oat5 urinary levels as a 83 
specific biomarker of AKI. To accomplish that aim, we evaluated if urinary excretion of 84 
exosomal Oat5 returns to its basal levels when cisplatin renal damage is prevented by the co-85 
administration of the renoprotective compound N-acetylcysteine. Four days after cisplatin 86 
administration, AKI was induced in cisplatin-treated male Wistar rats (Cis group), as it was 87 
corroborated by increased urea and creatinine plasma levels. Tubular damage was also observed. 88 
In co-treated animals (Cis+NAC group), plasma urea and creatinine concentrations tended to 89 
return to their basal values and tubular damage was improved. Urinary excretion of exosomal 90 
Oat5 was notably increased in Cis group, but when renal injury was ameliorated by N-91 
acetylcysteine co-administration, that increase was undetected. So, in this work we observed that 92 
urinary excretion of exosomal Oat5 was only increased if renal insult is produced, demonstrating 93 
its specificity as a renal injury biomarker. 94 
 95 
KEYWORDS: Acute kidney injury, Biomarker, Cisplatin, Organic Anion Transporter 5, Urinary 96 
exosomes 97 
 98 
99 
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INTRODUCTION 100 
Cisplatin (cis-diamminedichloroplatinum II) is a commonly chemotherapeutic agent used 101 
to treat different types of cancers, such as ovarian, testis, bladder, head and neck cancers, among 102 
many others. Nephrotoxicity is one of the most serious and prevalent side effects of cisplatin 103 
treatment and is often dose-limiting.
1,2
 It can be present mainly as acute kidney injury (AKI). 104 
Only a few days after initiating treatment, approximately one-third of the patients exhibited 105 
reduced glomerular filtration rate, higher creatinine and urea plasma levels and tubular damage.
3-5 106 
Intense efforts have been done in order to reduce cisplatin nephrotoxicity, such as hydration 107 
regimens, which includes the use of either mannitol or furosemide. Nevertheless, there is no good 108 
evidence that diuretics provide any additional benefit and kidney injury prevalence is still high.
1,4
 109 
The kidney accumulates cisplatin to a greater degree than other organs, principally in 110 
proximal tubular cells. The mechanisms of cisplatin-induced nephrotoxicity are complex and 111 
involve multiple pathways and molecules. Oxidative stress is one of the most implicated 112 
mechanisms in the pathogenesis of cisplatin cytotoxic effects.
4,6
 N-acetylcysteine (NAC), an 113 
aminothiol compound, is an antioxidant that was originally introduced as a mucolytic agent. 114 
More recently, NAC has been used to prevent kidney injury following the administration of 115 
iodinated contrast media.
7
 It acts as scavenger of oxidant species, restoring cellular antioxidant 116 
potential, and it replenishes depleted glutathione levels by free radicals, inhibits neutrophil 117 
activity and Tumor Necrosis Factor production. Recently, it has been reported that the treatment 118 
of Wistar rats with NAC markedly reduced cisplatin-induced apoptosis in tubular cells and 119 
improved the glomerular and tubular functions of the kidney.
8-10
 120 
Organic anion transporter 5, Oat5 (Slc22a19), belongs to the organic anion transporter 121 
(Oat) family and it is expressed exclusively in the kidney in the apical membranes of proximal 122 
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tubules cells. It acts as an organic anion/dicarboxylate exchanger and it has been reported that it 123 
transports ochratoxin A, dehydroepiandrosterone sulfate (DHEA-S) and estrone-3-sulfate (ES), 124 
and interacts with many others anionic drugs.
11-14 
Our group was pioneering in detecting Oat5 in 125 
urine.
15
 We have found an important increase in Oat5 urinary excretion in ischemia, in mercury 126 
and in cisplatin-induced AKI.
15-18 
The present study was designated to demonstrate the specific 127 
response of the urinary excretion of exosomal Oat5 to kidney injury independently of other 128 
cisplatin toxical effects, in order to strengthen Oat5 urinary levels as a specific biomarker of AKI. 129 
To accomplish that objective, we evaluated if the urinary excretion of exosomal Oat5 returns to 130 
its basal levels when renal damage produced by cisplatin is prevented by the co-administration of 131 
an antioxidant compound such as NAC. 132 
 133 
EXPERIMENTAL PROCEDURES  134 
 135 
Materials 136 
Chemicals were purchased from Sigma (St. Louis, MO, USA) and were analytical grade 137 
pure.  138 
Animals Treatments 139 
Male Wistar rats (120 days, 360-410 g body weight (body wt)) were used. Animals had 140 
free access to food and tap water, and were housed in an environment of constant temperature 141 
(21-23 ºC) and humidity with regular light cycles (12 hours) during the experiments. The animals 142 
were cared for in accordance with principles and guidelines for the care and use of laboratory 143 
animals, recommended by the National Academy of Sciences and published by the National 144 
Institute of Health (NHI publication 7
th
 edition revised 1996) and recommended by regulations of 145 
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the local ethics committee. All experimental procedures were approved by the Faculty of 146 
Biochemical and Pharmaceutical Sciences Institutional Animal Care and Use Committee. 147 
The animals were randomly divided into four experimental groups: Control group (n=6): 148 
rats were injected intraperitoneally (i.p.) with cisplatin vehicle (1 mL saline/kg body wt) at day 0 149 
and also received a daily i.p. injection of NAC vehicle (0.5 mL saline/100 g body wt) for 4 150 
consecutive days; Cis group (n=6): this group was given a single injection of cisplatin (5 mg/kg 151 
body wt, i.p.) at day 0, and a daily i.p. injection of NAC vehicle for 4 consecutive days; NAC 152 
group (n=4): rats received a single i.p. injection of cisplatin vehicle at day 0 and 500 mg/kg body 153 
wt, i.p. of NAC daily for 4 days; Cis+NAC group (n=6): this group received a single dose of 154 
cisplatin at day 0 (5 mg/kg body wt, i.p.) and they were also injected with NAC solution (500 155 
mg/kg body wt, i.p.) once a day for 4 days. The cisplatin dose and the days of treatment were 156 
selected based on previous results obtained in a dose-finding toxicity study and in a time course 157 
study of that dose in order to establish clear kidney toxicity without letality.
17,18 
 Additionally, the 158 
dose of cisplatin used in this study is approximately equivalent to a dose of 29,8 mg/m
2
 in 159 
humans,
19
 that is included in the cisplatin dosage range.
20
 NAC dose employed was selected in 160 
order to show its renoprotective effect in cisplatin-induced nephrotoxicity based on previous 161 
studies.
8,9
 162 
Animals were sacrificed 4 days after cisplatin (or its vehicle) administration. For surgical 163 
procedures the animals were anesthetized with sodium thiopental (70 mg/kg body wt, i.p.). The 164 
animals were maintained in metabolic cages for 24 h before the experiments in order to collect 165 
their urines, and all urine samples were collected using protease inhibitor (phenylmethylsulfonyl 166 
fluoride, PMSF 100 mM). Animals had access to water ad libitum throughout urine collection 167 
periods. Urinary volume was estimated by gravimetry, and urine flow rate (VU, mL/min. 100g 168 
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body wt) was also calculated. Later, urines samples were centrifuged at 1000 x g 10 min in order 169 
to remove cellular debries. An aliquot of the supernatant was removed from each sample for 170 
biochemical determinations, and the remaining supernatant immediately stored at -80°C until 171 
exosomes isolation.
21 
On the day of the experiments, plasma samples were obtained by cardiac 172 
puncture and kidney tissue was collected. 173 
This study has been performed in an in vivo model, using tumour-free animals. Previous 174 
studies have demonstrated that 4 mg/kg body wt of cisplatin significantly inhibited tumour 175 
growth in rats and caused a marked nephrotoxicity, without compromising the survival of the 176 
animals.
22
 In addition, it has been observed that NAC administration provides renoprotection in a 177 
cisplatin-induced nephrotoxicity model, without reducing cisplatin antitumoral efficacy.
23
 178 
Two different sets of experimental animals were used: one for urine and blood assays, 179 
urinary exosomes isolation and preparation of homogenates and apical membranes from whole 180 
kidney, another for histopathological and immunohistochemical studies. 181 
 182 
Biochemical determinations 183 
The urine samples were used for the analyses of alkaline phosphatase (AP) activity and 184 
creatinine (CrU), total proteins and glucose levels. Serum samples were used to measure urea and 185 
creatinine levels (Crp). 186 
Urine AP activity, creatinine, total proteins and glucose levels, as well as plasma urea and 187 
creatinine levels were determined spectrophotometrically with commercial reagent kits (Wiener 188 
Laboratory, Rosario, Argentina). Creatinine clearance (ClCr) was calculated using the formulae: 189 
ClCr = (CrU x VU) / Crp.  190 
 191 
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Histopathological and Immunohistochemistry studies 192 
The histopathological studies and the immunohistochemistry technique were performed as 193 
previously described.
15-18 
Kidneys from the different experimental groups were briefly perfused 194 
with saline, followed by perfusion with periodate-lysine-paraformaldehyde solution (0.0375 M 195 
phosphate buffer (pH 6.20) containing 0.01 M NaIO4, 0.075 M lysine, 2% paraformaldehyde), 196 
through a cannula inserted in the abdominal aorta. The kidney slices were immersed in periodate-197 
lysine-paraformaldehyde solution at 4ºC overnight. After that, the tissue was embedded in 198 
paraffin and paraffin sections were cut. 199 
After deparaffining, some sections were used for routine haematoxylin-eosin staining, 200 
while others were incubated with 3% H2O2 for 15 min (in order to eliminate endogenous 201 
peroxidase activity) to perform Oat5 renal immunohistochemistry. Then, the sections were 202 
incubated with blocking serum for 30 min and after that with non-commercial rabbit polyclonal 203 
antibody against rat Oat5 (diluted 1:100,
12
) overnight at 4ºC. The sections were rinsed with Tris-204 
Buffered Saline containing 1% Tween (TBST). Right after, the sections were incubated with 205 
horseradish peroxidase (HPR) conjugated secondary antibody against rabbit immunoglobulin for 206 
1 hour. So as to detect HPR labelling, a peroxidase substrate solution with diaminobenzidine 207 
(0.05% diaminobenzidine in TBST with 0.05% H2O2) was used. The sections were 208 
counterstained with hematoxylin before being examined under a light microscope. Controls using 209 
preimmune serum, antiserum absorbed with excess synthetic peptide, or omission of primary or 210 
secondary antibody revealed no labelling. 211 
 212 
 213 
 214 
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Preparation of homogenates and apical membranes from kidney 215 
Apical membranes were isolated from kidneys by Mg/EGTA precipitation as previously 216 
described.
15-18
 At first, the kidneys were removed and homogenized in 30 g/100 mL of ice-cold 217 
2mM Tris HCl buffer (pH 7.10) containing 50 mM mannitol, 5 mM EGTA and 1 mM PMSF, for 218 
5 min at top speed in a Glas-Col homogenizer. From this preparation we obtained total renal 219 
homogenates, and aliquots were taken and stored at -80ºC until use. After that, MgCl2 was added 220 
to the rest of the homogenate to a final concentration of 12 mM and the mixture was stirred in an 221 
ice bath for 15 min. The homogenate was then centrifuged (3,000 x g, 15 min, 4ºC). The 222 
supernatant obtained was decanted and centrifuged again at 28,000 x g for 40 min at 4ºC. The 223 
pelleted material representing apical membranes was resuspended in “experimental buffer” (10 224 
mM hepes-Tris (pH 7.50), 50 mM mannitol, and 1 mM PMSF) and centrifuged for 15 min at 800 225 
x g at 4ºC. The supernatant was finally centrifuged for 45 min at 28,000 x g. The apical 226 
membrane pellets thus obtained were resuspended in experimental buffer, and aliquots of the 227 
membranes were stored at -80ºC until used. Protein quantification of samples was performed 228 
using the method of Lowry with some modifications.
24
 229 
 230 
Isolation of urinary exosomes 231 
Urinary exosomes were isolated from urine as previously described.
18,25
 Urine samples 232 
were extensively vortexed right away after thawing. Later, they were centrifuged at 17,000 x g 233 
for 15 min at 4ºC, in order to remove large membrane fragments, whole cells and other debris. 234 
After that, the supernatants were ultracentrifuged at 200,000 x g for 1 h at 4°C (Optima
TM
 XL-235 
100 K Ultracentrifuge, Beckam Coulter, Inc.; Ti 80 rotor), in order to purify the exosomes. The 236 
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pellets obtained were resuspended in isolation solution (10 mM triethanolamine, 250mM sucrose, 237 
0.3 mM PMSF, pH 7.60). 238 
 Tamm-Horsfall protein is an abundant urinary protein that forms very high molecular 239 
weight complexes that sediment in the ultracentrifugation step unless denatured. To denature 240 
their zona pellucida domains, we added to the resuspended pellets dithiothreitol (DTT, 200 241 
mg/mL) and after that, they were incubated at 95°C for 2 min. Afterwards, they were put into an 242 
ultracentrifuge tube and isolation solution was added in order to increase the volume up to 8 mL. 243 
The samples were then ultracentrifuged again at 200,000 x g for 1 h at 4°C. The final pellets were 244 
resuspended in an adequate volume of isolation solution and immediately frozen at -80°C until 245 
used. 246 
In order to asses if this protocol used to isolate urinary exosomes was efficient, we tested 247 
the presence of AQP2 in the 200,000 x g ultracentrifugation pellet by Western blotting. AQP2 is 248 
considered a specific urinary exosome-associated protein.
26
 We detected a clear protein band in 249 
200,000 x g final pellet, with identical molecular weight to that observed in total urine (data not 250 
shown). 251 
 252 
Electrophoresis and Immunoblotting 253 
Homogenates (20 µg of protein), apical membranes (16 µg of protein) and urinary 254 
exosomes samples (10 μL) were boiled for 3 min in the presence of 1% 2-mercaptoethanol, 2% 255 
sodium dodecyl sulphate (SDS) and separated by 8.5% polyacrylamide gel (SDS-PAGE). Later, 256 
they were electroblotted to nitrocellulose membranes. In order to verify equal protein loading and 257 
transfer between lanes, Ponceau Red was used as previously described.
15-18
 The nitrocellulose 258 
membranes were incubated with 5% non-fat dry milk in Phosphate-Buffered Saline containing 259 
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0.1% Tween 20 (PBST) for 1 h. After being rinsed with PBST, the membranes were then 260 
incubated overnight at 4ºC with a non-commercial rabbit polyclonal antibody against rat Oat5 (at 261 
a dilution of 1:800). The specificity of Oat5 antibody has been described elsewhere.
12
 262 
Afterwards, the membranes were incubated for 1 hour with a peroxidase coupled goat anti-rabbit 263 
IgG (Bio-Rad Laboratories, Hercules, CA, USA) after further washing with PBST. Blots were 264 
processed for detection using a commercial kit (ECL enhanced chemiluminescence system, 265 
Amersham, Buckinghmshire, UK). A densitometric quantification of the Western blot signal 266 
intensity of membranes was performed. For densitometry of immunoblots, samples from treated 267 
rats were run on each gel with corresponding control samples. The abundance of Oat5 in the 268 
kidney homogenates or apical membranes samples from the treated animals was calculated as 269 
percentage of the mean control value for that gel, set as 100%. For Oat5 abundance in urinary 270 
exosomes, each value after normalization to urinary creatinine content was expressed as % of the 271 
mean value from control group, as previously described.
18
 272 
 273 
Statistical analysis 274 
 The statistical analysis was performed using one way ANOVA followed by the Newman-275 
Keuls test. p values of less than 0.05 were considered significant. The results are expressed as the 276 
means ± standard error (SEM). For these analyses, GraphPad software was used (Version 3, San 277 
Diego, CA, USA). 278 
 279 
RESULTS 280 
The renoprotective effect of NAC on cisplatin renal damage was assessed in order to 281 
characterize the experimental model. As it is shown in Figure 1, cisplatin caused a statistically 282 
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significant increase in creatinine and urea plasma levels and a significant decrease in creatinine 283 
clearance, as compared with Control group. These results show that the dose of cisplatin 284 
employed in this work produced AKI in rats 4 days after its administration. In Cis+NAC group, 285 
NAC co-administration ameliorated the increases observed in plasma urea and creatinine levels 286 
and significantly ameliorated the decrease in creatinine clearance values observed in animals 287 
treated with cisplatin alone (Cis group). 288 
Histopathological studies revealed that cisplatin-treated animals showed alterations in 289 
their normal tubular structure as tubular desquamation cells, tubular dilatation, and epithelial cell 290 
detachment from basement membranes. Meanwhile, Cis+NAC group showed a notably 291 
improvement in their tubular structure, as compared with renal tissue from Cis rats (see Figure 2). 292 
The histological findings observed in this work were in agreement with those previously 293 
described.
8
 294 
Tubular damage was also assessed using biochemical parameters. Urinary glucose, total 295 
proteins levels and urine AP activity were related to urinary creatinine concentrations in order to 296 
correct for variations in urine production as previously described for urinary transporters and 297 
enzymes.
15-18
 As it is shown in Figure 3, cisplatin caused a significantly increase in the three 298 
urinary parameters evaluated, as compared with control animals. These results indicate a 299 
significant tubular damage, as it was corroborated by histological findings. In the Cis+NAC 300 
group, NAC prevented the increases observed in these parameters. This could be due to 301 
renoprotective effects of NAC administration.
8
 NAC alone did not modify any of the three 302 
tubular parameters evaluated. 303 
Oat5 abundance in urine was evaluated in exosomal urinary fraction because they provide 304 
an enriched low-abundance urinary proteins source. Its abundance in urinary exosomes was also 305 
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related to urinary creatinine concentrations in order to correct for variations in urine production. 306 
Figure 4 shows an important increase in Oat5 abundance in urinary exosomes in Cis rats (almost 307 
an increase of 200%), as compared with control values. NAC treated animals exhibited a 308 
decrease in Oat5 abundance in urinary exosomes (a decrease of approximately 40%). Cis + NAC 309 
group showed Oat5 abundance values in urinary exosomes similar to NAC group, showing that 310 
NAC prevented the increase observed in urinary excretion of exosomal Oat5 in cisplatin treated 311 
rats. 312 
Oat5 renal expression was also evaluated. Figure 5 shows a significantly decrease in Oat5 313 
renal expression in Cis animals in renal homogenates as well as in apical membrane (55 and 50 314 
%, respectively), as compared to control values. In NAC group, Oat5 abundance was increased in 315 
renal homogenates (approximately 50%) meanwhile it was no significantly modified in apical 316 
membranes. In the Cis+NAC group, renal homogenates and apical membranes Oat5 expressions 317 
were decreased, as compared with control values, but in homogenates this decrease was less 318 
marked than in Cis group, whereas in apical membranes the decrease observed was almost the 319 
same as in Cis group (Figures 5 A, B). Oat5 renal expression was also assessed by 320 
immunohistochemistry technique. As it is shown in Figure 6, Oat5 labelling in Cis, NAC and 321 
Cis+NAC was consistent with the density observed by Western blotting studies in each 322 
experimental group. Negative controls with omission of primary antibody revealed no labelling 323 
for the four different experimental groups. 324 
 325 
DISCUSSION 326 
Cisplatin is one of the most effective and broadly used drugs for the treatment of adult and 327 
pediatric different types of cancers, such as gastric, esophageal, bladder and head and neck 328 
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cancers, between many others.
27
 A major dose-limiting side effect of cisplatin is nephrotoxicity, 329 
where it can appear in different ways, but the most serious and more common presentation is 330 
AKI, which occurs in 20–30% of patients. The nephrotoxicity could be reduced, but not totally 331 
prevented, by fractionating the dose or enforced diuresis with diuretics and hydration. Hydration 332 
expands the post-renal volume thus reducing cisplatin concentration in the tubular cells, and is 333 
commonly done with a normal saline solution alone, or combined with mannitol or furosemide. 334 
However, the effectiveness of the enforced diuresis is still controversial and high incidence of 335 
nephrotoxicity stills occurs.
28-30
 Therefore, changes in the renal function should be carefully 336 
monitored for early detection and diagnosis of renal damage during cisplatin administration.
31
 337 
Blood urea nitrogen and serum creatinine levels are the most commonly used markers of 338 
kidney injury. Nevertheless, both are neither sensitive nor specific, and do not adequately 339 
differentiate between the different stages of AKI. Based on the above, intense efforts have been 340 
done in order to find a better biomarker for early and accurately AKI detection. Urine has 341 
provided the most encouraging candidates, such as kidney injury molecule-1 (KIM-1)
32
 and 342 
neutrophil gelatinase-associated lipocalin (NGAL),
33
 between many others. Related to this issue, 343 
in the last years we have been trying to validate Oat5 in urine as a novel, early and non-invasive 344 
biomarker of AKI of different etiologies. Oat5 is an organic anion/dicarboxylate exchanger that 345 
localizes exclusively in apical membranes of renal proximal tubules. Because of its ability to 346 
exchange organic anions for four and five carbon dicarboxylates, it has been proposed that it is 347 
the renal organic anion transporter that may function as an apical pathway for the reabsorption of 348 
several organic anions driven by an outward gradient of α-ketoglutarate and/or succinate.12,13 In 349 
2009, we have proposed urinary Oat5 excretion as a novel and early biomarker of ischemic 350 
AKI.
15
 Latter, in 2010, Oat5 in urine has been proposed as an early biomarker of mercuric-351 
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induced AKI.
16
 And currently, we are evaluating Oat5 urinary excretion as a possible non-352 
invasive and early biomarker of cisplatin-induced AKI. In spite of all these efforts, several issues 353 
must be addressed before pass from pre-clinical animal trials to clinical research, in order to 354 
highlight the importance of this novel urinary biomarker of AKI. On that subject, it would be 355 
useful to evaluate if in cisplatin-induced AKI model, Oat5 urinary excretion returns to its basal 356 
levels if renal injury is prevented with, for example, an antioxidant compound such as NAC, to 357 
corroborate its utility as a specific biomarker of kidney injury. NAC is a thiol-containing 358 
antioxidant and it has been probed that it could inhibit cisplatin-induced glutathione depletion, 359 
hydrogen peroxide accumulation, and lipid peroxidation. Into this regards, it has been proposed 360 
that NAC has protective effects in cisplatin-induced nephrotoxicity in human and in rats.
8,23,34
  361 
In this study, we corroborated the renoprotective effect of NAC on cisplatin-induced 362 
kidney injury, described by other authors, and mainly we evaluated the effect of NAC on Oat5 363 
urinary excretion, specifically in the exosomal urinary fraction, in cisplatin-treated animals. 364 
Exosomes are nanovesicles of about 40-100 nm of diameter. They are formed intracellularly 365 
within multivesicular endosomes and latter are released into extracellular space by different types 366 
of cells from diverse tissues and organs, and they could be found in biological fluids, such as 367 
urine and blood. It has been reported that exosomes emerge as a consequence of cellular response 368 
to a different kind of stresses, like oxidative stress, heat shock and hypoxia. Proteins derived from 369 
renal epithelia from cells throughout the renal tract have been identified by proteomic analysis of 370 
urinary exosomes. They also provide an enriched low-abundance urinary proteins source of 371 
proteins that have a potential pathophysiological significance.
35,36
 In this regards, proteins that are 372 
known to be involved in specific kidney diseases such as aquaporin 2, AQP-2, (Autosomal 373 
dominant and recessive nephrogenic diabetes insipidus) and Na
+
-K
+
-2Cl
-
 cotransporter-2, 374 
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NKCC2, (Antenatal Bartter syndrome type I) have been discovered in urinary exosomes and 375 
proposed as potential biomarker of kidney disease.
25
 Related to this issue, we were the first 376 
working group in detecting Oat5 in urinary exosomes. On that subject, in this work we observed 377 
that cisplatin caused an important increase of exosomal Oat5 urinary excretion four days after its 378 
administration and NAC co-administration prevented that increase. Oat5 expression was found 379 
decreased in homogenates and in apical membranes, in cisplatin treated rats. Cisplatin may 380 
decrease Oat5 renal expression by increasing its degradation or decreasing its synthesis probably 381 
due to oxidative stress produced in proximal tubules cells. About that, studies in cell cultures as 382 
well as in animal models indicated that inhibition of protein synthesis is one of the earliest 383 
biochemical manifestations of cisplatin toxicity in proximal tubular studies.
37
 In Cis+NAC 384 
animals, Oat5 expression in renal homogenates was significantly higher than in Cis group but still 385 
decreased as compared with control values; meanwhile in apical membranes Oat5 expression was 386 
significantly decreased and no significant changes were found as compared with Cis group. The 387 
fact that a complete recovery of Oat5 renal expression levels have not been seen in Cis+NAC 388 
group despite NAC treatment reduced cisplatin-induced renal injury could be only a matter of 389 
time. In favour of this hypothesis is the moderate increase observed in Oat5 levels in 390 
homogenates in Cis+NAC animals as compared with Cis group, suggesting that Oat5 renal 391 
synthesis recovering has begun.  NAC, acting as a scavenger of free radical of oxygen and as an 392 
antioxidant compound could be preventing cisplatin-induced alterations in protein synthesis or 393 
degradation. In this connection, it has been found that Oat1 and Oat3, two closely related 394 
transporters to Oat5, have shown a similar expression profile in a cisplatin-induced AKI model, 395 
where renal injury was ameliorated by a JBP485 (Cyclo-trans-4-L-hydroxyprolyl-L-serine, a 396 
compound with antioxidant properties). On that subject, Oat1 and Oat3 renal expressions were 397 
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significantly decreased in cisplatin-treated rats, which also exhibited renal impairment. Although 398 
JBP484 could improved renal function when was co-administrated to cisplatin-treated rats, Oat1 399 
and Oat3 did not increased their renal expressions, as compared with the cisplatin alone group.
38
  400 
Oat5 renal expression may have a physiological role in the homeostasis of sulfate 401 
conjugates such as ES and DHEAS. Both compounds represent a pool of inactive steroids in 402 
mammalian blood, which in several tissues can be enzimatically converted into active hormones 403 
(estrone, DHEA and estradiol). It was described that in mammalian kidneys, ES and DHEAS are 404 
reabsorbed. So Oat5 may be involved in this process, re-internalizing the filtered ES and 405 
DHEAS in exchange for intracellular succinate and α-ketoglutarate.39 Nevertheless, the exact 406 
functional role of Oat5 is still unknown. Moreover, the physiological role proposed in the 407 
homeostasis of inactive steroids does not explain the role or participation of this transporter in 408 
the physiophatology of cisplatin-induced nephrotoxicity. On the other hand, previous studies 409 
have described that dicarboxylates are essential for the recovery of proximal tubules cells after 410 
an important renal damage.
40,41
 As it has been already described, Oat5 internalizes organic anion 411 
in exchange for intracellular succinate and α-ketoglutarate. Therefore, in cisplatin-treated 412 
animals, the surviving proximal tubules cells might tend to preserve intracellular dicarboxylates 413 
(such as succinate and α-ketoglutarate), by decreasing the Oat5 apical membrane expression and 414 
increasing Oat5 urinary excretion, as a protective response after tubular renal injury caused by 415 
the administration of cisplatin. 416 
In conclusion, urinary excretion of exosomal Oat5 is notably increased after AKI is 417 
produced by cisplatin administration. When this renal injury is prevented or ameliorated by the 418 
co-administration of a renoprotective compound such as NAC, that increase in urinary excretion 419 
of exosomal Oat5 is not observed, demonstrating that exosomal Oat5 urinary levels are increased 420 
20 
 
 20 
only if renal insult is produced, highlighting its specificity as a biomarker of renal damage. The 421 
results observed in this work, together with previous valuable data obtained by our group, could 422 
let as to firmly suggest that Oat5 urinary excretion could be used as a specific, early, non-423 
invasive and novel urinary biomarker of AKI in an animal model of this pathology. Additional 424 
work is needed to fully understand the performance of this biomarker in kidney injuries of other 425 
etiologies and to fully understand the mechanisms involved in Oat5 urinary excretion. Also, the 426 
next step would be passing from pre-clinical animal trials to clinical research in order to also 427 
demonstrate its utility as an early biomarker of AKI in humans. On that subject, it is important to 428 
mention that preliminary studies carried in our laboratory, detected one band with rat anti-Oat5 429 
antibody in urine samples from four adult healthy humans with identical molecular weight to that 430 
observed in rat urine (Trebucobich, M. S., Hazelhoff M. H., Bulacio R. P., Brandoni A. and 431 
Torres, A. M., unpublished data,). Current experiments are performed in our laboratory in order 432 
to characterize the nature of the protein detected in human urine with rat anti-Oat5 antibody and 433 
to evaluate Oat5 urinary excretion in AKI from different etiologies. 434 
Nevertheless, we have to be aware of, as many authors support; it is likely that a panel of 435 
biomarkers, rather than a single biomarker, will be needed to accurately detect different types of 436 
AKI in different types of patients and in diverse situations.
42-44
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FIGURE LEGENDS 590 
 591 
Figure 1: (A) Urea (g/L) and (B) creatinine plasma levels (mg/L) and (C) renal creatinine 592 
clearance (mL/24h/100g body wt) in Control (n=6), Cis (n=6), NAC (n=4) and Cis + NAC (n=6) 593 
after four days of treatment. Results are expressed as mean values ± SEM. (a) p < 0.05 versus 594 
Control, (b) p < 0.05 versus Cis, (c) p < 0.05 versus NAC, (d) p < 0.05 versus Cis + NAC. 595 
Figure 2: Optical microscopy photos of kidney histology in Control (a), Cis (b), NAC (c) and 596 
Cis + NAC (d) after four days of treatment. (Hematoxylin-eosin staining). No histological 597 
alterations were found in Control and NAC groups, meanwhile in rats treated with cisplatin 598 
tubular damage was observed, showing tubular desquamation cells (asterisk), tubular dilatation 599 
(arrow head), and epithelial cell detachment from basement membranes (arrow) (b). On the other 600 
hand, Cis + NAC renal tissue showed a notably improvement in tubular architecture, as compared 601 
with renal tissue from cisplatin treated rats (d). These pictures are representatives of samples 602 
obtained from 4 animals from each experimental group. Bars 40 µm. 603 
Figure 3: Glucose (g/g creatinine) (A) and total proteins (g/g creatinine) (B) urinary levels and 604 
AP urinary activity (IU/g creatinine) (C) in Control (n=6), Cis (n=6), NAC (n=4) and Cis + NAC 605 
(n=6) groups after four days of treatment. These parameters were related to urinary creatinine 606 
concentration in order to correct for variations in urine production. Results are expressed as mean 607 
values ± SEM. (a) p < 0.05 versus Control, (b) p < 0.05 versus Cis, (c) p < 0.05 versus NAC, (d) 608 
p < 0.05 versus Cis + NAC. 609 
Figure 4: Oat5 abundance in urinary exosomes from Control, Cis, NAC and Cis + NAC animals 610 
after four days of treatment. The samples were separated by SDS-PAGE and blotted onto 611 
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nitrocellulose membranes. Densitometric quantification of Oat5 Western blotting from urinary 612 
exosomes are expressed as arbitrary units related to urinary creatinine concentration in order to 613 
correct for variations in urine production. The mean of the control value was set as 100%. Results 614 
are expressed as mean values ± SEM from experiments carried out in four different samples for 615 
each experimental group. (a) p < 0.05 versus Control, (b) p < 0.05 versus Cis, (c) p < 0.05 versus 616 
NAC, (d) p < 0.05 versus Cis + NAC. 617 
Figure 5: Representatives immunoblots for Oat5 in homogenates (A) and apical membranes (B) 618 
from kidneys of Control, Cis, NAC and Cis + NAC rats. Proteins were separated by SDS-PAGE 619 
and blotted onto nitrocellulose membranes. The results are expressed as percentage. The mean of 620 
the control value was set as 100%. Results are expressed as mean values ± SEM from 621 
experiments carried out in four different preparations for each experimental group. (a) p < 0.05 622 
versus Control, (b) p < 0.05 versus Cis, (c) p < 0.05 versus NAC, (d) p < 0.05 versus Cis + NAC. 623 
Figure 6: Immunohistochemistry for Oat5 in renal tissue from Control (a), Cis (b), NAC (c) and 624 
Cis + NAC (d) rats after four days of treatment. Serial sections from each rat kidney were stained 625 
using a non-commercial anti-Oat5 antibody. Oat5 labeling was associated with the apical plasma 626 
membranes (arrow) and with intracellular domains (arrowhead) in proximal tubule cells (a). 627 
These pictures are representatives of typical samples obtained from 4 animals from each 628 
experimental group. Bars 40 µm. 629 
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